Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15428491 | 1.00 | MAPT (0.47) | MAPTPKMALDH1A1KDM4ETSHR | |
| SCHEMBL14244289 | 1.00 | MAPT (0.47) | MAPTPKMALDH1A1KDM4ETSHR | |
| SCHEMBL28600953 | 1.00 | MAPT (0.47) | MAPTPKMALDH1A1KDM4ETSHR | |
| SCHEMBL15235893 | 0.89 | ALDH1A1 (0.55) | MAPTPKMALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL6082774 | 0.89 | ALDH1A1 (0.55) | MAPTPKMALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL15977387 | 0.89 | ALDH1A1 (0.55) | MAPTPKMALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL7182 | 0.86 | TSHR (0.48) | MAPTPKMALDH1A1TSHRCA12 | |
| SCHEMBL15213234 | 0.86 | SLC9A1 (0.50) | MAPTPKMALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL14622854 | 0.86 | SLC9A1 (0.50) | MAPTPKMALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL20572278 | 0.86 | MAPT (0.46) | MAPTPKMALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383908-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | HINOVA PHARMACEUTICALS INC. (CN) | 2024-11-21 | — | — | US | disclosed |
| CN-115594666-B | Synthesis and application of phosphatase degradation agent | 海创药业股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4368614-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | Hinova Pharmaceuticals Inc. (CN) | 2024-05-15 | — | — | EP | disclosed |
| CN-115594666-A | Synthesis and application of phosphatase degrading agent | 海创药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2023280237-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | 海创药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2023280237-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | 海创药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| EP-3409671-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-21 | — | — | EP | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICALS NV (BE) | 2020-04-14 | — | — | US | disclosed |
| US-7968155-B2 | Optically anisotropic material, liquid crystal display device and triphenylene compound | FUJIFILM CORPORATION (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7872716-B2 | Optical compensation film, polarizing plate and liquid crystal display | FUJIFILM CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7462713-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7431971-B2 | Retardation plate | FUJIFILM CORPORATION (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20080192191-A1 | Optical Compensation Film, Polarizing Plate and Liquid Crystal Display | FUJIFILM CORPORATION (JP) | 2008-08-14 | — | — | US | disclosed |
| EP-1585749-B1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1947102-A1 | Compositions comprising diazepinoindole derivatives as kinase inhibitors | Pfizer, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070281111-A1 | Optically Anisotropic Material, Liquid Crystal Display Device and Triphenylene Compound | FUJIFILM CORPORATION (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281111-A1 | Optically Anisotropic Material, Liquid Crystal Display Device and Triphenylene Compound | DVL1, DVL3, FZD7 | MAPT 361/4885PKM 3011/4885ALDH1A1 1879/4885 |
| US-20240383908-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | DUSP1, PPM1D, PTPN1 | MAPT 3181/4885PKM 1943/4885ALDH1A1 1769/4885 |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | CHEK1, CHEK2, CHKA | MAPT 3427/4885PKM 482/4885ALDH1A1 4198/4885 |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | GPR119, GLP1R, GCGR | MAPT 4611/4885PKM 3459/4885ALDH1A1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.